Peptide therapy TikTok claims: separating signal from hype

What did @andreampm23 actually say?

The creator, a personal trainer and gym owner, argued that weight loss injections are not "absolutely necessary" unless someone has already committed to consistent dieting for at least a month. She shared that she lost 58 pounds postpartum in seven months using cardio, strength training, and diet alone. She was careful not to condemn peptides or semaglutide outright, saying she is "not against the use of any of these things." Her main concern is that people now believe they "cannot lose weight without using these things." That framing matters. She is not making a medical claim. She is making a motivational one, and the distinction is worth paying attention to.

Does the science back this up?

On the core claim, yes, mostly. Consistent caloric deficit remains the most evidence-backed mechanism for weight loss. A 2022 meta-analysis by Tobias et al. in The Lancet Diabetes and Endocrinology confirmed that dietary adherence, not diet type, is the strongest predictor of sustained weight loss. Her 58-pound loss in seven months works out to roughly 2 pounds per week, which is aggressive but within the documented range for postpartum women with high initial body weight and structured exercise. That said, her suggestion that one month of consistent dieting is a fair trial before considering medical intervention is not a clinical standard. Obesity medicine specialists typically evaluate patients over longer periods and consider multiple physiological factors, not just willpower and effort. Her implicit framing that peptide use is primarily a shortcut rather than a treatment for a chronic condition is where the science starts to push back.

What did they get wrong (or right)?

She got the motivational core right. Natural weight loss is still achievable for many people, and the idea that it is not has become genuinely problematic in online fitness culture. Credit where it is due.

But she got a few things wrong or at least incomplete. First, calling semaglutide a "peptide" in the same breath as experimental research compounds like BPC-157 or semax muddles an important distinction. Semaglutide is an FDA-approved GLP-1 receptor agonist with robust clinical trial data behind it. Grouping it casually with unregulated peptides does a disservice to both categories.

Second, her framing that people use these drugs because they believe they "cannot" lose weight naturally oversimplifies the clinical reality of obesity. Research by Sumithran et al. (2011, New England Journal of Medicine) showed that sustained caloric restriction triggers hormonal adaptations, including drops in leptin and peptide YY, that actively drive hunger and fat storage back. For some patients, that is not a mindset problem. It is a metabolic one.

Third, her comment that she does not know the "long term or short term side effects" of semaglutide is fair on long-term data but understates the existing short-term safety profile, which has been studied in trials involving thousands of participants.

What should you actually know?

Weight loss medications, including GLP-1 agonists like semaglutide and tirzepatide, are not a replacement for effort. But they are also not just a shortcut for people who have not tried hard enough. The clinical criteria for prescribing them exist for a reason. Obesity is classified as a chronic disease by the American Medical Association, and treating it with medication is not categorically different from treating hypertension or type 2 diabetes with medication.

What this creator is pushing back against is real, though. There is a growing social narrative that natural methods are obsolete, and that framing does discourage people from trying lifestyle changes that would genuinely work for them. Her personal results are legitimate data points, even if they are not universal ones.

The practical takeaway is this: if you are considering any weight loss intervention, whether dietary, pharmaceutical, or peptide-based, the conversation should happen with a licensed clinician who can evaluate your full history. Not a TikTok comment section, and not this fact-check either.

The bottom line on peptides specifically

It is worth noting that most of the peptides in this video's category, including BPC-157, TB-500, semax, and selank, have no FDA approval and limited or no large-scale human trial data. They are not the same as semaglutide, which has completed phase 3 clinical trials. Anyone treating these compounds as interchangeable with approved medications is making a serious category error. The creator did not make that error explicitly, but the video's placement in the peptide category invites that conflation.